Last reviewed · How we verify

Truvada and Isentress — Competitive Intelligence Brief

Truvada and Isentress (Truvada and Isentress) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI and INSTI. Area: Infectious disease.

phase 3 NRTI and INSTI Reverse transcriptase and integrase Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

Truvada and Isentress (Truvada and Isentress) — Projeto Praça Onze. Truvada is a combination of emtricitabine and tenofovir disoproxil fumarate, which are nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection. Isentress is a HIV integrase strand transfer inhibitor (INSTI) used to treat HIV-1 infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Truvada and Isentress TARGET Truvada and Isentress Projeto Praça Onze phase 3 NRTI and INSTI Reverse transcriptase and integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI and INSTI class)

  1. Projeto Praça Onze · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Truvada and Isentress — Competitive Intelligence Brief. https://druglandscape.com/ci/truvada-and-isentress. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: